Jefferies Starts ProNAi Therapeutics (DNAI) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Wedbush Starts ProNAi Therapeutics (DNAI) at Outperform
August 10, 2015 7:34 AM EDTWedbush initiates coverage on ProNAi Therapeutics (NASDAQ: DNAI) with a Outperform rating and a price target of $36.00.
Analyst David Nierengarten commented, "DNAI is a clinical-stage biotech company developing a novel therapeutic platform based on DNA interference (DNAi). ProNAi's lead candidate, PNT2258, is a... More
BofA/Merrill Lynch Starts ProNAi Therapeutics (DNAI) at Buy
August 10, 2015 7:26 AM EDTBofA/Merrill Lynch initiated coverage on ProNAi Therapeutics (NASDAQ: DNAI) with a Buy rating and a price target of $35.00.
For an analyst ratings summary and ratings history on ProNAi Therapeutics click here. For more ratings news on ProNAi Therapeutics click here.
Shares of ProNAi Therapeutics closed at $28.56 yesterday.
... More